公开(公告)号：US20070129548A1

公开(公告)日：2007-06-07

申请号：US11633152

申请日：2006-12-04

申请人： Lushi Tan ,  Robert Meissner ,  Wenjie Li ,  James Perkins ,  Aaron Cote ,  Joyce Stellabott ,  Yuan-Hon Kiang

发明人： Lushi Tan ,  Robert Meissner ,  Wenjie Li ,  James Perkins ,  Aaron Cote ,  Joyce Stellabott ,  Yuan-Hon Kiang

IPC分类号： A61K31/4745 ,  C07D471/02

CPC分类号： C07J73/005 ,  C07D471/04

摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

摘要翻译： 结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤 手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生 ），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

公开(公告)号：US20160311834A1

公开(公告)日：2016-10-27

申请号：US15032663

申请日：2014-10-24

申请人： Michael McNEVIN ,  Yong LIU ,  Ian MANGION ,  Alfred LEE ,  Joyce STELLABOTT ,  Benjamin D. SHERRY ,  Gary MARTIN ,  Kung-I FENG ,  Scott SHULTZ ,  Ryan COHEN ,  Yanfeng ZHANG

发明人： Michael McNEVIN ,  Yong LIU ,  Ian MANGION ,  Alfred LEE ,  Joyce STELLABOTT ,  Benjamin D. SHERRY ,  Gary MARTIN ,  Kung-I FENG ,  Scott SHULTZ ,  Ryan COHEN ,  Yanfeng ZHANG

IPC分类号： C07D498/04 ,  A61K45/06 ,  A61K31/5383

CPC分类号： C07D498/04 ,  A61K31/5365 ,  A61K45/06 ,  A61P1/16

摘要： The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.

摘要翻译： 本发明涉及化合物A的新型伪多晶型物，包含至少一种化合物A的假多晶型物的组合物，以及使用化合物A的假多晶型物制备用于治疗或预防患者HCV感染的组合物的方法，其中化合物A具有结构 。

公开(公告)号：US20210361663A1

公开(公告)日：2021-11-25

申请号：US17286620

申请日：2019-10-21

申请人： Sutthilug SOTTHIVIRAT ,  Joyce STELLABOTT ,  Walter R. WASYLASCHUK ,  Merck Sharp & Dohme Corp.

发明人： Sutthilug Sotthivirat ,  Joyce Stellabott ,  Walter R. Wasylaschuk

IPC分类号： A61K31/5365 ,  A61K9/20

摘要： The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C vims NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations.

公开(公告)号：US07365202B2

公开(公告)日：2008-04-29

申请号：US11633152

申请日：2006-12-04

申请人： Lushi Tan ,  Robert S. Meissner ,  Wenjie Li ,  James J. Perkins ,  Aaron S. Cote ,  Joyce Stellabott ,  Yuan-Hon Kiang

发明人： Lushi Tan ,  Robert S. Meissner ,  Wenjie Li ,  James J. Perkins ,  Aaron S. Cote ,  Joyce Stellabott ,  Yuan-Hon Kiang

IPC分类号： C07D221/18

CPC分类号： C07J73/005 ,  C07D471/04

摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

摘要翻译： 结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。 这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤 手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生 ），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。